Randomized Clinical Trial of Bococizumab (PF-04950615; RN316) in Subjects With Hyperlipidemia or Mixed Dyslipidemia at Risk of Cardiovascular Events
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 2139 participants.
Also called NCT01968967
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 2,139 participants
- Sponsor
- Registry
-
NCT01968967 -
2013-002643-28
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Canada, Colombia, France, Hungary, Lithuania, Mexico, Romania, Russia, Spain, Taiwan, United Kingdom
- Registry status
- Completed
Technical summary
Registry record NCT01968967. Randomized; quadruple masking; primary purpose treatment. Start 2013-10-29 (actual); primary completion 2016-07-05 (actual). Results posted on 2017-07-24.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Randomized Clinical Trial of Bococizumab (PF-04950615; RN316) in Subjects With Hyperlipidemia or Mixed Dyslipidemia at Risk of Cardiovascular Events
- Acronym
- SPIRE-LDL
- Condition
- Hyperlipidemia
- Intervention (Drug)
- Bococizumab (PF-04950615; RN316)
- Intervention (Other)
- Placebo
- Lead sponsor
- Pfizer
Record details
- Record id
cardio:ct-nct01968967- Content hash
d9fa72ca044844a8faa73fe34ddbafccfc7f2b733ed25e174a0eefaf1e2857ce